PReS-FINAL-2033: Increase of adverse mild and moderate adverse events among patients with juvenile idiopathic arthritis treated with biological therapies

Antzeko izenburuak

• PReS-FINAL-2032: Changes in immunogenic profile in patients with juvenile idiopathic arthritis exposed to anti tumoral necrosis factor therapy
  nork: Guillen Astete, CA, et al.
  Argitaratua: (2013)
• PReS-FINAL-2168: Comparison of safety and retention rate of TNF antagonist therapy in juvenile-onset and adult-onset ankylosing spondylitis: data from the spanish registry biobadaser 2.0
  nork: Sifuentes Giraldo, WA, et al.
  Argitaratua: (2013)
• PReS-FINAL-2115: Differences in musculoskeletal clinical expression between Spanish and Mexican patients with juvenile spondyloarthritis: data from the Mexespa project
  nork: Sifuentes Giraldo, WA, et al.
  Argitaratua: (2013)
• PReS-FINAL-2043: Cardiac involvement in juvenile idiopathic arthritis
  nork: Rossetto, E, et al.
  Argitaratua: (2013)
• PReS-FINAL-2147: Immunological consequences of biologicals in juvenile idiopathic arthritis
  nork: Swart, JF, et al.
  Argitaratua: (2013)